key: cord-0946573-tq877z9u authors: Dulek, Daniel E.; Mueller, Nicolas J. title: Pneumonia in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice date: 2019-04-23 journal: Clin Transplant DOI: 10.1111/ctr.13545 sha: 37e58367f56d10d7ffdb5c0d9a98b5c4df95015d doc_id: 946573 cord_uid: tq877z9u These guidelines from the AST Infectious Diseases Community of Practice review the diagnosis and management of pneumonia in the post‐transplant period. Clinical presentations and differential diagnosis for pneumonia in the solid organ transplant recipient are reviewed. A two‐tier approach is proposed based on the net state of immunosuppression and the severity of presentation. With a lower risk of opportunistic, hospital‐acquired, or exposure‐specific pathogens and a non‐severe presentation, empirical therapy may be initiated under close clinical observation. In all other patients, or those not responding to the initial therapy, a more aggressive diagnostic approach including sampling of tissue for microbiological and pathological testing is warranted. Given the broad range of potential pathogens, a microbiological diagnosis is often key for optimal care. Given the limited literature comparatively evaluating diagnostic approaches to pneumonia in the solid organ transplant recipient, much of the proposed diagnostic algorithm reflects clinical experience rather than evidence‐based data. It should serve as a template which may be modified according to local needs. The same holds true for the suggested empiric therapies, which need to be adapted to the local resistance patterns. Further study is needed to comparatively evaluate diagnostic and empiric treatment strategies in SOT recipients. The clinical presentation of pneumonia in the SOT recipient is highly variable. The traditional presentation with cough, increased sputum production, and fever should always prompt evaluation for pneumonia. However, frequently more subtle symptoms predominate with the diagnosis of pneumonia being reached only after careful clinical evaluation. Clinical evolution can vary from very rapid, indicative of bacterial or viral pathogens, to the subacute or chronic presentation often seen with fungal or mycobacterial infections. A high index of suspicion for pneumonia is essential when any signs of infection are present in a solid organ transplant recipient. Lung involvement should be evaluated in any transplant patient presenting with an unexplained fever, even in the absence of other lung-specific clinical findings. The differential diagnosis for pneumonia in SOT recipients includes infectious and non-infectious etiologies (Table 1 ). An understanding of infectious etiologies in these patients is driven by epidemiologic investigation of both transplanted [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and otherwise healthy adult and pediatric patients. 13, 14 In earlier eras, studies of pneumonia in SOT recipients were focused on the high incidence of opportunistic infections such as invasive mold infections and cytomegalovirus (CMV). 12 With improved infection prevention strategies, better diagnostic tools, and newer immunosuppressive strategies, the importance of community-acquired bacterial and viral infection in SOT-associated pneumonia has been increasingly appreciated. 2 The differential diagnosis of pneumonia in SOT recipients depends upon a multitude of non-specific factors including but not limited to age and timing post-transplant, net state of immunosuppression, specific organ transplanted, environmental exposures, site of pneumonia acquisition (community vs. healthcare/hospital-acquired), and radiographic infiltrate pattern. The risk of pneumonia in SOT recipients is determined by the degree/depth of immunosuppression. 15 Healthcare and/or ventilator-associated pneumonia are frequently diagnosed in the early post-transplant period. In two series, early onset pneumonia post-liver transplant was dominated by bacterial etiologies, the majority of which were Gram-negative bacilli. 7, 8 The majority of pneumonia episodes occur later post-transplant with 50% occurring >1 year post-transplant 9 in renal recipients and 70.4% of episodes occurring at >6 months post-transplant in a multicenter point prevalence study. 2 The type of organ transplanted influences the incidence, timing, and microbiologic spectrum of pneumonia in SOT recipients. 16 Lung transplantation poses unique challenges given the potential for donor-derived infection and recipient airway colonization to impact the occurrence and microbiology of pneumonia. In a prospective, multicenter study of pneumonia in lung transplant recipients, pneumonia incidence was 72 episodes per 100 lung transplants per year. 3 Though bacterial pneumonia was the most frequent etiology, fungal An array of non-infectious etiologies can mimic infectious pneumonia in the SOT recipient (Table 1) . Post-transplant lymphoproliferative disease (PTLD) may present with lung/thoracic involvement including pulmonary nodules and mediastinal adenopathy, especially in lung/heart-lung transplant recipients. 68, 69 Pulmonary PTLD can also radiographically mimic infectious etiologies of pneumonia. 70 mTOR inhibitor-induced pneumonitis is an infrequent though potentially severe medication side effect that generally resolves with discontinuation of mTOR inhibitor therapy and may co-exist with infectious etiologies including PJP or community-acquired respiratory viruses. 71 Non-PTLD primary or metastatic lung cancer can also occur in SOT recipients. 72 Other complications such as pulmonary embolism, pulmonary hemorrhage, and pulmonary edema are also reported. 73,74 No studies have prospectively compared diagnostic approaches to pneumonia in SOT recipients. While some specific diagnostic tests have been evaluated more systematically, individual test performance is often defined in healthy subjects or in groups of subjects with a variety of immunocompromising conditions. Therefore, the appropriate diagnostic evaluation for pneumonia in SOT recipients should be highly individualized based on local epidemiology, locally available tests, and practice parameters, as well as patient-specific risk factors, exposures, and medical history. Guidelines for diagnosis of pneumonia by other groups can also be informative though do not always specifically apply to the SOT recipient. [75] [76] [77] [78] A tiered approach to the diagnostic evaluation of pneumonia encompasses an initial approach, followed by a more extensive evaluation if the diagnosis remains unclear or if the patient is deteriorating. If the clinical situation is critical or if a more specific diagnosis is initially suspected, respective tests are applied and the order of diagnostic tests modified. One potential diagnostic approach to pneumonia in the SOT recipient is outlined in Figure 1 . • The diagnostic evaluation of SOT recipients with suspected or confirmed pneumonia should be performed using a tiered approach with the pace and extent of evaluation informed by the severity and acuity of presentation, the degree of immunosuppression, and the patient's risk factor/exposure history (strong, low). • We recommend against using current pneumonia severity scores in SOT recipients with pneumonia (strong, very low o The acuity of the patient's clinical presentation and use of this information in guiding the differential diagnosis, diagnostic evaluation, and empiric antimicrobial therapy (strong, low). • The need for contact or respiratory isolation should be assessed and acted upon early in the patient evaluation to avoid exposure of other SOT recipients, patients, and/or staff to potentially contagious pathogens (strong, high). 81 • Local epidemiology of respiratory viruses, and in particular influenza virus, should be reviewed and considered in the evaluation (strong, high). 54 The initial evaluation of a SOT recipient with pneumonia should include both blood and radiologic testing with consideration given to viral detection from the nasopharynx. • Clinicians should obtain complete blood count with differential, electrolyte chemistries, and liver function testing as part of the initial laboratory evaluation both for aiding in diagnosis and de- The contribution of inflammatory markers (leukocyte count, C-reactive protein, procalcitonin) has been extensively studied as a tool for the general practitioner to decide whether empiric antibiotic treatment may be necessary with mixed results. 86 Several studies have evaluated the utility of procalcitonin measurement for detecting and differentiating bacterial infection from other solid organ transplant complications, 87-94 reviewed in. 95 Importantly, procalcitonin levels are impacted by surgery as well as by ATG administration which may decrease the utility of this assay in first week post-transplant. 95 • Laboratory tests not obtained as part of the initial evaluation should be performed (weak, low). • If not done yet, a CT scan of the chest should be performed to better delineate the radiologic pattern and location of infiltrate and to identity potential opportunity for invasive diagnostic procedures (strong, high). • Additional blood testing guided by radiographic pattern, exposures, and degree of immunosuppression should include antigen and/or serologic evaluation for endemic mycoses (strong, high) 47 (see Endemic Fungi section of 4th edition of AST ID Guidelines). • Fungal biomarkers measured in the blood/serum, such as galactomannan and 1,3β-d-glucan, have poor performance characteristics in SOT recipients as compared with HSCT recipients. 18, 96, 97 No studies have evaluated whether performance characteristics In some cases, more invasive testing is needed to obtain a diagnosis. Invasive, procedural diagnostic testing in the SOT recipient with pneumonia includes bronchoscopy with bronchoalveolar lavage (BAL), transbronchial biopsy, CT-guided biopsy, video-assisted thoracotomy (VATS) with lung biopsy, and open lung biopsy. These procedures are particularly important for the diagnosis of fungal disease (see the Aspergillus, Cryptococcus, Endemic Fungi, and Emerging Fungi sections of 4th edition of AST ID Guidelines) and to evaluate for non-infectious causes such as malignancy. Though potential exists for achieving a diagnosis with one of these methods, the decision to pursue further procedural evaluation in an SOT recipient with pneumonia must balance both procedural risks and potential benefits. • Physicians caring for an SOT recipient with pneumonia should have a low threshold for procedural evaluation especially in settings in which patients are not improving, are highly immunocompromised, or the diagnosis remains uncertain (strong, moderate). Bronchoalveolar lavage offers the opportunity to obtain microbiologic diagnosis either with or without transbronchial biopsy. The utility of BAL in SOT recipients with pneumonia, lung infiltrates, or lung nodules has been evaluated in several small series. 5, 22, 68, 101, 102 Microbiologic yield for BAL in these studies ranges from 39% to 77%, with the highest yields in patients with nosocomial pneumonia, 5 and those with onset of symptoms between 1 and 6 months post-transplant. 102 Importantly, microbiologic yield is clearly influenced by the pre-test probability of infection and the relative incidence of infections in distinct populations. 102, 103 BAL studies listed in Figure 1 are proposed as a complete list of diagnostic options. While extensive, performance of the complete list of these studies may not be needed in all SOT recipients with pneumonia. • We recommend the performance of BAL in the setting of diffuse or focal pulmonary infiltrate in patients with failure to improve on empiric antibacterial therapy in whom diagnosis has not been reached by non-invasive testing (strong, moderate). The decision to proceed with BAL versus lung biopsy for initial invasive testing must be highly individualized for each patient and is dependent on the clinician's risk/benefit analysis. Biopsy-based evaluation offers the ability to directly identify infectious agents in tissue and also determine the histologic pattern of inflammation present. Open lung biopsy (OLB) was studied in a singlecenter kidney transplant population with bilateral lung infiltrates. 105 The overall OLB diagnostic yield was 85.1% with findings from 53% of OLBs resulting in a therapeutic management change. Complications were frequent (28.7% of OLBs) and associated with higher mortality rate. 105 A similar study comparing SOT and non-SOT patients with diffuse lung disease demonstrated a therapeutic management change frequency of 33%. 106 Percutaneous CT-guided lung biopsy has been evaluated in one series of SOT recipients with parenchymal lung nodule(s). 107 Diagnostic yield in this series of 45 biopsies was 53% with the most frequent diagnoses being fungal disease and malignancy. Yield was highest with the use of both fine-needle aspiration and core biopsy combined in the procedure. Complications occurred in 13% of patients. 107 The decision to proceed with lung biopsy must be highly individualized for each patient and is dependent on the clinician's risk/ benefit analysis. • We recommend lung biopsy (Open, VATS, or CT-guided) in the setting of diffuse or focal pulmonary infiltrate in patients with failure to improve on empiric antibacterial therapy and in whom diagnosis has not been reached by non-invasive testing or BAL (strong, moderate). • We recommend lung biopsy (transbronchial, Open, VATS, or CTguided) for patients with focal pulmonary nodule(s) where diagnosis has not already been established by other means due to the risk for malignancy (including PTLD) or invasive fungal infection (weak, low). Consideration can be given to close follow-up with serial imaging prior to performance of invasive diagnostic procedures for cases in which the risk for malignancy and/or invasive fungal infection is felt to be low (weak, low). • In patients who live in geographic areas that impart risk for endemic fungal infection and who have exposure history suggestive of a moderate to high risk for endemic fungal infection, we recommend deferral of lung biopsy until after antigen/serologic assessment for endemic fungal infection is complete (weak, low). Non-hypothesis-driven tests such as broad-spectrum bacterial PCR based on 16sRNA, panfungal, or mycobacterial genus PCR are not universally available and not systemically studied in SOT recipients. However, these assays may be helpful in patients where all other tests do not identify an etiology. Unbiased next-generation sequencing may assist in defining a specific etiology if available, though more clinical studies are needed to define the utility of a sequencing-based diagnostic approach to pneumonia. • In a stable patient considered suitable for outpatient therapy who is at lower risk for opportunistic or hospital-acquired infection and in whom no specific pathogen is suspected, empiric therapy should cover community-acquired pneumonia and should follow national/international guidelines influenced by local resistance and prevalence patterns (strong, low). Betalactams or fluoroquinolones (FQ) with coverage of respiratory pathogens may be considered for empiric therapy in this setting (strong, low). Practitioners should consider the role of drug interactions, adverse reactions, and increasing antimicrobial resistance when considering risks and benefits for the FQ use in SOT recipients. • Consideration should be given to empiric coverage of intracellular pathogens (such as Mycoplasma pneumoniae, Chlamydia pneumonia, and Legionella spp) in SOT recipients with community-acquired pneumonia (weak, low) with greater consideration given to empiric intracellular pathogen treatment of pediatric SOT recipients with community-acquired pneumonia (strong, moderate). 13, 14 One important consideration is the selection and use of empiric therapy in this setting in which drug-drug interactions are present between macrolides and immunosuppressive agents. Respiratory fluoroquinolones may be considered in settings with a high incidence of macrolide resistance for Mycoplasma spp with consideration given to the above-noted issues in considering risk and benefit of FQ use (weak, low). • In SOT recipients who require hospitalization for pneumonia, combination therapy with a beta-lactam agent (±MRSA and ±antipseudomonal activity) and an agent active against intracellular organisms (Mycoplasma spp in children and Legionella spp in adults) is recommended (strong, low). The breadth of coverage of the penicillin-based agent used depends on local resistance patterns (especially for S pneumoniae) and whether a nosocomial approach is warranted to cover hospital-acquired gram-negative pathogens (eg, recent hospitalization, underlying chronic or bronchiectatic lung disease, or the presence prosthetic material). Fluoroquinolones are an alternative in this setting (strong, low). For hospitalized patients with nosocomial or ventilator-associated pneumonia, international/ national guidelines apply with attention to local guidelines, prevalence, and epidemiology (strong, moderate). Any empiric therapy must be adapted to new clinical and microbiological findings. As appropriateness of initial empiric therapy is measured in large part by the patient's clinical response, close monitoring including repeated clinical evaluation is a prerequisite for any outpatient approach. If this is not feasible or if any doubts prevail, inpatient management should be favored. Furthermore, with any empiric therapy for pneumonia, key gaps in antimicrobial coverage must be kept in mind. Most empiric regimens will not optimally treat Nocardia spp or Pneumocystis jirovecii. Mycobacterial infections may be partially mitigated by the activity of drugs used for empiric pneumonia therapy (eg, imipenem, quinolones, and oxazolidinones). In addition, empiric antibacterial regimens will clearly not provide coverage against invasive, opportunistic, and/or endemic fungal infections. Clinicians caring for SOT recipients with subacute or chronic illness presentations which include pneumonia should consider pathogens such as Nocardia, tuberculosis, non-tuberculous mycobacteria, endemic fungi, and invasive molds. These pathogens require bronchoalveolar fluid or tissue testing for diagnosis and their treatment entails prolonged courses of antimicrobial regimens. Empiric therapy is usually not instituted prior to diagnostic testing or procedure. However, in unique situations of high acuity or inability to perform diagnostic procedures, empiric therapy for these pathogens may be needed. The diagnosis and treatment of pneumonia in the SOT recipient is challenging due to varied clinical presentations, numerous potential etiologies, and breadth of both empiric and targeted treatment options. Diagnostic strategies must consider numerous factors including post-transplant timing, degree of immunosuppression, environmental/community/hospital exposures, and seasonal epidemiology. Empiric treatment is in large part determined by local epidemiology and resistance patterns. Novel diagnostic techniques and future prospective studies will continue to impact the diagnosis and treatment of pneumonia in SOT recipients. The authors declare no conflict of interests. The incidence and costs of sepsis and pneumonia before and after renal transplantation in the United States Pneumonia in solid organ transplant recipients: a prospective multicenter study Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study Pneumonia after heart transplantation: a multi-institutional study Microbiologic features and outcome of pneumonia in transplanted patients Etiology and microbial patterns of pulmonary infiltrates in patients with orthotopic liver transplantation Early-onset pneumonia after liver transplantation: microbiological findings and therapeutic consequences Etiologies, risk factors, and outcomes of bacterial pneumonia after living donor liver transplantation Epidemiology of pneumonia in kidney transplantation Pulmonary complications in renal recipients after transplantation Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies Community-acquired pneumonia requiring hospitalization among U.S. children Community-acquired pneumonia requiring hospitalization among U.S. Adults Infection in solid-organ transplant recipients Nosocomial infections within the first month of solid organ transplantation Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation Infection among adult small bowel and multivisceral transplant recipients in the 30-day postoperative period Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients Pulmonary infiltrates in immunosuppressed patients: analysis of a diagnostic protocol Pulmonary disease in liver transplant recipients: Spectrum of CT features Pulmonary nodules in lung transplant recipients: etiology and outcome Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2000 cases Endemic fungal infection recommendations for solid-organ transplant recipients and donors Travelrelated disseminated Penicillium marneffei infection in a renal transplant patient Expect the unexpected: pleuro-pulmonary melioidosis in a renal transplant recipient Rhodococcus equi infection Tularemia in a kidney transplant recipient: an unsuspected case and literature review Pulmonary infection caused by Rhodococcus equi in a kidney and pancreas transplant recipient: a case report Zoonoses in solid-organ and hematopoietic stem cell transplant recipients Epidemiology, bacteriology and control of an outbreak of Nocardia asteroides infection on a liver unit Respiratory syncytial virus seasonality: a global overview Global influenza seasonality to inform country-level vaccine programs: an analysis of WHO FluNet influenza surveillance data between Invasive pneumococcal infections in children following transplantation in the pneumococcal conjugate vaccine era Invasive pneumococcal disease in solid organ transplant recipients-10-year prospective population surveillance Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study A 20-year experience with nocardiosis in solid organ transplant (SOT) recipients in the Southwestern United States: a single-center study Nocardia infection in solid organ transplant recipients: a multicenter European Case-Control Study Opportunistic pulmonary infections in solid organ transplant recipients Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation Pneumocystis pneumonia outbreak among renal transplant recipients at a North American transplant center: risk factors and implications for infection control Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients Histoplasmosis after solid organ transplant Cryptococcal infections in solid organ transplant recipients over a 15-year period at a state transplant center Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases A cluster of donor-derived Cryptococcus neoformans infection affecting lung, liver, and kidney transplant recipients: Case report and review of literature Epidemiology of cryptococcosis and cryptococcal meningitis in a large retrospective cohort of patients after solid organ transplantation A surveillance study of adenovirus infection in adult solid organ transplant recipients Adenovirus disease after kidney transplantation: course of infection and outcome in relation to blood viral load and immune recovery A five-year prospective multi-center evaluation of influenza infection in transplant recipients A multicenter consortium to define the epidemiology and outcomes of pediatric solid organ transplant recipients with inpatient respiratory virus infection Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes Human metapneumovirus infection: pneumonia risk factors in patients with solid organ transplantation and computed tomography findings Respiratory tract infections due to human metapneumovirus in immunocompromised children Influenza virus infection in adult solid organ transplant recipients Secondary bacterial infections associated with influenza pandemics Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study Respiratory viral infections within one year after pediatric lung transplant Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study Toxoplasma gondii pneumonia in liver transplantation: survival after a severe case of reactivation Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis Strongyloides stercoralis hyperinfection transmitted by liver allograft in a transplant recipient Single donor-derived strongyloidiasis in three solid organ transplant recipients: case series and review of the literature Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors Epstein-Barr viral loads do not predict post-transplant lymphoproliferative disorder in pediatric lung transplant recipients: A multicenter prospective cohort study Pulmonary posttransplant lymphoproliferative disorder with a CT halo sign Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase III clinical trial program of everolimus and review of the literature Lung cancer prognosis in elderly solid organ transplant recipients Noninfectious pulmonary complications of liver, heart, and kidney transplantation: an update Acute respiratory failure in kidney transplant recipients: a multicenter study The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the infectious diseases society of America and the American society for microbiology Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis Predicting pneumonia mortality using CURB-65, PSI, and patient characteristics in patients presenting to the emergency department of a comprehensive cancer center guideline for isolation precautions: preventing transmission of infectious agents in health care settings Legionnaires' disease in transplant recipients: a 15-year retrospective study in a tertiary referral center Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study A randomized, controlled trial of the impact of early and rapid diagnosis of viral infections in children brought to an emergency department with febrile respiratory tract illnesses The effect of rapid respiratory viral diagnostic testing on antibiotic use in a children's hospital Procalcitonin-guided use of antibiotics for lower respiratory tract infection Diagnostic value of serum procalcitonin in solid organ transplant recipients: a systematic review and meta-analysis Comparison between procalcitonin, serum amyloid A, and C-reactive protein as markers of serious bacterial and fungal infections after solid organ transplantation Procalcitonin for infections in the first week after pediatric liver transplantation Kinetic of procalcitonin in the early postoperative course following heart transplantation Role of biomarkers in early infectious complications after lung transplantation Early identification of infectious complications in lung transplant recipients using procalcitonin Post-operative kinetics of procalcitonin after lung transplantation Perioperative changes of procalcitonin levels in patients undergoing liver transplantation The use and value of procalcitonin in solid organ transplantation Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation Bronchoalveolar lavage fluid (1,3)beta-D-glucan for the diagnosis of invasive fungal infections in solid organ transplantation: a Prospective Multicenter Study Contribution of (1,3)-beta-D-glucan to diagnosis of invasive candidiasis after liver transplantation Diagnostic accuracy of bronchoalveolar lavage samples in immunosuppressed patients with suspected pneumonia: analysis of a protocol Clinical usefulness of bronchoalveolar lavage in heart transplant recipients with suspected lower respiratory tract infection Diagnostic utility of flexible bronchoscopy in recipients of solid organ transplants Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients The diagnostic yield and complications of open lung biopsies in kidney transplant patients with pulmonary disease Open lung biopsy for diffuse disease in patients with and without previously transplanted solid organs The diagnostic yield of CT-guided percutaneous lung biopsy in solid organ transplant recipients Delay of adequate empiric antibiotic therapy is associated with increased mortality among solid-organ transplant patients on behalf of the AST Infectious Diseases Community of Practice. Pneumonia in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice